• Protocol Short Name and Number: SR-aGVHD, 2002
• Protocol Long Name: A Phase 3, Randomized, Open-Label, Multicenter Study, to Compare T-Guard to Ruxolitinib for the Treatment of Patients with Grade III or IV Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)
• Protocol Synopsis (PDF)
• ICFs (PDF)
• FAQs (PDF)
• Key Personnel

1. • BMT CTN # 2002 Co-Chair: John Levine, MD
   • BMT CTN # 2002 Co-Chair: Gabby Meyers, MD
   • BMT CTN # 2002 Co-Chair: Gérard Socié, MD
   • BMT CTN # 2002 Protocol Officer: Mehdi Hamadani, MD
   • BMT CTN # 2002 Protocol Coordinator: DJ White; 2002DCC@emmes.com

• Protocol Short Name and Number: BEAT-MS, 1905
• Protocol Long Name: A Multicenter Randomized Controlled Trial of Best Available Therapy versus Autologous Hematopoietic Stem Cell Transplant for Treatment-Resistant Relapsing
• Key Personnel​​​​

1. • BMT CTN 1905 Co-Chair: Jeffrey A. Cohen, MD
   • BMT CTN 1905 Co-Chair: George E. Georges, MD
   • BMT CTN 1905 Co-Chair: Paolo A. Muraro, MD, PhD
   • BMT CTN 1905 Chair: Marcelo Pasquini, MD; mpasquini@mcw.edu
   • NIAID Protocol Coordinator: Sean McCarthy, RN, MS; sean.mccarthy@nih.org
   • BMT CTN DCC Coordinator: Amy Foley; afoley@nmdp.org

Note: For the ITN077AI / BMT CTN 1905 study, the BMT CTN is endorsing the study and providing accrual credit. Centers participate via NIAID/Immune Tolerance Network (ITN). BMT CTN Centers will receive both NIAID/ITN and BMT CTN accrual credits. For questions about the study and how to participate or to access study materials, contact the NIAID protocol coordinator, Sean McCarthy, at sean.mccarthy@nih.gov.

• Protocol Short Name and Number: HIV T-cell, 1903
• Protocol Long Name: (AMC-109) - Administration of HIV-specific T cells to HIV+ Patients Receiving High Dose Chemotherapy Followed by Autologous Stem Cell Rescue -Auto-RESIST
• Protocol (PDF)
• ICFs (PDF)
• FAQs (PDF)
• Key Personnel
•  
• BMT CTN # 1903 Co-Chair: Rich Ambinder, MD
• BMT CTN # 1903 Co-Chair: Kieron Dunleavy, MD
• BMT CTN # 1903 Protocol Officer: Steve Devine, MD
• BMT CTN # 1903 Protocol Coordinator: Christine Borchert; bmtctn1903@emmes.com

• Protocol Short Name and Number: T-Guard for SR aGVHD, 1802
• Protocol Long Name: An Open-Label, Single-Arm, Multicenter Study of Combination anti- CD3/CD7 Immunotoxin (T-Guard) for Steroid-Refractory Acute Graft- versus-Host Disease
• Protocol Synopsis (PDF)
• Key Personnel

1. • BMT CTN # 1802 Co-Chair: John Levine, MD
   • BMT CTN # 1802 Co-Chair: Gabrielle Meyers, MD
   • BMT CTN # 1802 Protocol Officer: Mehdi Hamadani, MD

• Protocol Short Name and Number: AAT GVHD Treatment, 1705
• Protocol Long Name: A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase III Trial of Alpha 1 – Antitrypsin (AAT) Combined with Corticosteroids vs Corticosteroids Alone for the Treatment of High Risk Acute Graft-versus-Host Disease (GVHD) Following Allogeneic Hematopoietic Stem Cell Transplant
• Protocol (PDF)
• ICFs (PDF)
• FAQs (PDF)
• Key Personnel

1. • BMT CTN # Co-Chair: Amin Alousi
   • BMT CTN # Co-Chair: John Magenau
   • Protocol Officer: Mehdi Hamadani, MD
   • Protocol Coordinator: Lindsey Haroun; bmtctn1705@emmes.com

• Protocol Short Name and Number: PROGRESS III – PTCY vs. TAC/MTX / Mi-Immune, 1703/1801
• Protocol Long Name:

1. • BMT CTN 1703: A Randomized, Multicenter, Phase III Trial of Tacrolimus/Methotrexate versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation
   • BMT CTN 1801: Companion Study: Microbiome and Immune Reconstitution in Cellular Therapies and Hematopoietic Stem Cell Transplantation (Mi-Immune)

• Protocol (PDF)
• ICFs (PDF)
• FAQs (PDF)
• Key Personnel (BMT CTN 1703)

1. • BMT CTN # 1703 Co-Chair: Shernan Holtan, MD
   • BMT CTN # 1703 Co-Chair: Javier Bolanos-Meade, MD
   • BMT CTN # 1703 Protocol Officer: Mehdi Hamadani, MD
   • BMT CTN # 1703 Protocol Coordinator: Kristy Applegate, MBA; bmtctn1703@emmes.com

• Key Personnel (BMT CTN 1801)

1. • BMT CTN # 1801 Co-Chair: Miguel-Angel Perales, MD
   • BMT CTN # 1801 Co-Chair: Leslie Kean, MD, PhD
   • BMT CTN # 1801 Co-Chair: Ami Bhatt, MD, PhD
   • BMT CTN # 1801 Protocol Officer: Wael Saber, MD, MS
   • BMT CTN # 1801 Protocol Coordinator: Kristy Applegate, MBA;  bmtctn1703@emmes.com

• Protocol Short Name and Number: ECOG-ACRIN EA4151 MCL, 1601
• Protocol Long Name: A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma In Minimal Residual Disease-Negative First Complete Remission
• Key Personnel

1. • BMT CTN # 1601 Protocol Chair: Timothy Fenske, MD
   • BMT CTN # 1601 Chair: Matthew Lunning, MD
   • BMT CTN # 1601 Protocol Coordinator: Christiana Samuel, csamuel@ecog-acrin.org     
   • BMT CTN # 1601 Protocol Coordinator: Amy Foley, afoley@nmdp.org

Note: For the ECOG-ACRIN EA4151/BMT CTN 1601 study, the BMT CTN is endorsing the study and providing accrual credit. Centers participate via their NCTN group. BMT CTN Centers will receive both NCTN and BMT CTN accrual credits. The protocol may be accessed through the CTSU website: https://www.ctsu.org  For questions about the study and how to participate, contact the ECOG-ACRIN protocol coordinator, Haleigh Wetzel, at hwetzel@ecog-acrin.org or 857-504-2900, or the CTSU Help Desk at  ctsucontact@westat.com or 1 888 823-5923.

• Protocol Short Name and Number: AML FLT3 Maintenance Therapy, 1506
• Protocol Long Name: A multi-center, randomized, double-blind, placebo-controlled Phase III trial of the FLT3 inhibitor gilteritinib administered as maintenance therapy following allogeneic transplant for patients with FLT3/ITD AML
• Protocol (PDF)
• Key Personnel

1. • BMT CTN # 1506 Co-Chair: Mark Levis, MD
   • BMT CTN # 1506 Co-Chair: Yi-Bin Chen, MD
   • BMT CTN # 1506 Protocol Officer: Mehdi Hamadani, MD
   • BMT CTN # 1506 Protocol Coordinator: Heather Wittsack and DJ White; 1506DCC@emmes.com

• Protocol Short Name and Number: STRIDE2, 1503
• Protocol Long Name: A Study to Compare Bone Marrow Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease
• Protocol (PDF)
• ICFs (PDF)
• FAQs (PDF)
• Key Personnel

1. • BMT CTN # 1503 Co-Chair: Lakshmanan Krishnamurti, MD
   • BMT CTN # 1503 Co-Chair: Mark Walters, MD
   • BMT CTN # 1503 Protocol Officer: Mary Eapen, MD, MS
   • BMT CTN # 1503 Protocol Coordinator: Delisha Crawford; bmtctn1503@emmes.com

• Protocol Short Name and Number: CNI-free GVHD (PROGRES II), 1301
• Protocol Long Name: A Randomized, Multi-Center, Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease
• Protocol (PDF)
• ICFs (PDF)
• FAQs (PDF)
• Key Personnel

1. • BMT CTN # 1301 Co-Chair: Miguel-Angel Perales, MD
   • BMT CTN # 1301 Co-Chair: Leo Luznik, MD
   • BMT CTN # 1301 Protocol Officer: Marcelo Pasquini, MD, MS
   • BMT CTN # 1301 Protocol Coordinator: Kristy Applegate, MBA; bmtctn1301@emmes.com

• Protocol Short Name and Number: RIC vs Hypometh for MDS, 1102
• Protocol Long Name: A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Intermediate-2 and High Risk Myelodysplastic Syndrome
• Protocol (PDF)
• ICFs (PDF)
• FAQs (PDF)
• Key Personnel

1. • BMT CTN # 1102 Co-Chair: Corey Cutler, MD, MPH, FRCP(C)
   • BMT CTN # 1102 Co-Chair: Ryotaro (Ryo) Nakamura, MD
   • BMT CTN # 1102 Protocol Officer: Wael Saber, MD, MS
   • BMT CTN # 1102 Protocol Coordinator: Kristy Applegate; bmtctn1102@emmes.com